H C Moore

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer
    H C Moore
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 2:587-93. 2000
  2. ncbi request reprint Managing menopause after breast cancer: balancing risks and benefits
    H C Moore
    Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 68:243-8. 2001
  3. ncbi request reprint Impact on quality of life of adjuvant therapy for breast cancer
    Halle C F Moore
    The Taussig Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 9:42-6. 2007
  4. ncbi request reprint Commentary: Ovarian function does not equal fertility does not equal babies
    Halle C F Moore
    The Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Oncologist 12:1067-9. 2007
  5. ncbi request reprint Discussing breast cancer and hormone replacement therapy with women
    Pelin Batur
    Department of General Internal Medicine, Gault Women s Health and Breast Pavilion, The Cleveland Clinic Foundation, Ohio 44195, USA
    Cleve Clin J Med 69:838, 840, 843-4 passim. 2002
  6. ncbi request reprint Menopausal hormone therapy (HT) in patients with breast cancer
    Pelin Batur
    Department of Internal Medicine, Section of Women s Health Cleveland Clinic Foundation, Crown Centre II, Independence, OH 44131, USA
    Maturitas 53:123-32. 2006
  7. ncbi request reprint Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623
    Halle C F Moore
    Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 25:1677-82. 2007
  8. doi request reprint Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series
    Khaldoun Almhanna
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Anticancer Drugs 19:217-9. 2008

Detail Information

Publications8

  1. ncbi request reprint Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer
    H C Moore
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 2:587-93. 2000
    ..Pregnancy after breast cancer is a realistic consideration for some breast cancer survivors and is not clearly detrimental to either the mother or her offspring...
  2. ncbi request reprint Managing menopause after breast cancer: balancing risks and benefits
    H C Moore
    Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 68:243-8. 2001
    ..This article explores the relationship between estrogens and breast cancer and discusses management options for a variety of menopausal complications in breast cancer survivors...
  3. ncbi request reprint Impact on quality of life of adjuvant therapy for breast cancer
    Halle C F Moore
    The Taussig Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 9:42-6. 2007
    ..Overall, however, quality of life is good for the majority of breast cancer survivors who have received adjuvant systemic therapy. Behavioral interventions that target fatigue and sleep disturbance may further enhance quality of life...
  4. ncbi request reprint Commentary: Ovarian function does not equal fertility does not equal babies
    Halle C F Moore
    The Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Oncologist 12:1067-9. 2007
  5. ncbi request reprint Discussing breast cancer and hormone replacement therapy with women
    Pelin Batur
    Department of General Internal Medicine, Gault Women s Health and Breast Pavilion, The Cleveland Clinic Foundation, Ohio 44195, USA
    Cleve Clin J Med 69:838, 840, 843-4 passim. 2002
    ..We discuss limitations of the study, questions that remain, and how to discuss the study with women at average risk and high risk for breast cancer...
  6. ncbi request reprint Menopausal hormone therapy (HT) in patients with breast cancer
    Pelin Batur
    Department of Internal Medicine, Section of Women s Health Cleveland Clinic Foundation, Crown Centre II, Independence, OH 44131, USA
    Maturitas 53:123-32. 2006
    ..To assess the effect of menopausal hormone therapy (HT) on reoccurrence, cancer-related mortality, and overall mortality after a diagnosis of breast cancer...
  7. ncbi request reprint Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623
    Halle C F Moore
    Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 25:1677-82. 2007
    ....
  8. doi request reprint Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series
    Khaldoun Almhanna
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Anticancer Drugs 19:217-9. 2008
    ..This class of drugs has been associated with delayed wound healing and thromboembolism. To our knowledge, this is the first case series of IVAD erosion through skin, in patients receiving such therapy...